MARKET

HARP

HARP

Harpoon Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.62
-0.36
-2.40%
After Hours: 14.62 0 0.00% 16:00 01/24 EST
OPEN
15.17
PREV CLOSE
14.98
HIGH
15.24
LOW
14.26
VOLUME
138.31K
TURNOVER
--
52 WEEK HIGH
21.47
52 WEEK LOW
9.07
MARKET CAP
349.55M
P/E (TTM)
-6.9573
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of HARP and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

HARP News

  • Top Insider Buys Highlight for the Week of Jan. 24
  • GuruFocus.com.1d ago
  • Trade Alert: The Chief Financial Officer Of Harpoon Therapeutics, Inc. (NASDAQ:HARP), Georgia Erbez, Has Just Spent US$94k Buying Shares
  • Simply Wall St..1d ago
  • FCEL, MBOT, PLX and TTPH among midday movers
  • Seeking Alpha - Article.12/27/2019 17:41
  • Mid-Day Market Update: Dow Up 70 Points; Pintec Technology Shares Spike Higher
  • Benzinga.12/27/2019 17:23

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About HARP

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct, or TriTAC, platform, the Company is developing a pipeline of T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Its TriTAC product candidate, HPN424, is focused on the treatment of metastatic castration-resistant prostate cancer, or mCRPC.
More

Webull offers Harpoon Therapeutics Inc (HARP) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.